• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Dec. 14, 2020

View Archived Issues
COVID-19 vaccine vials

Pfizer, Biontech bolster vaccine case after EUA; U.S. orders more Moderna vaccine

Following a recent string of emergency use authorizations (EUA) for their jointly developed COVID-19 vaccine, BNT-162b2, Pfizer Inc. and Biontech SE said Dec. 14 that results from an ongoing German trial have helped illustrate "the multiple arms of the immune system that are activated" by the product to fight SARS-CoV-2. Separately, Moderna Inc. raised to 200 million the number of doses of its COVID-19 vaccine candidate it will supply to the U.S. government. Read More
Coronavirus vaccine illustration

Let the vaccinations begin

A day after the FDA granted emergency authorization for the use of the Pfizer Inc./Biontech SE COVID-19 vaccine, the U.S. CDC’s Advisory Committee on Immunization Practices (ACIP) gave a thumb’s up for the vaccine, as did the Western States Scientific Safety Review Workgroup. Read More
Coronavirus vaccine illustration

Codagenix starts human study of COVID-19 vaccine; further Sputnik data unveiled

LONDON – The U.K. Medicines and Healthcare products Agency (MHRA) has given approval for the first-in-human study of Codagenix Inc.’s COVI-VAC, a live, attenuated whole virus COVID-19 vaccine, which is engineered to be structurally identical to wild-type SARS-CoV-2, but is much slower to replicate. Read More

A bigger bang: Astrazeneca acquires Alexion for $39B

In the biggest deal of a year packed with massive deals, Astrazeneca plc will buy Alexion Pharmaceuticals Inc. in a cash and stock transaction at $175 per share totaling $39 billion. Read More
Biotech deal illustration

Relay Therapeutics signs deal with Genentech for its SHP2 inhibitor

Cambridge, Mass.-based Relay Therapeutics Inc. has signed a lucrative worldwide license and collaboration agreement with Genentech, a member of the Roche Group, for the development and commercialization of its compound, RLY-1971, a potent inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2) that is being investigated in a phase I dose-escalation study in patients with advanced or metastatic solid tumors. Read More
Seedling-coins.png

Scineuro launches with $100M series A to target CNS

Scineuro Pharmaceuticals, based in Shanghai and Philadelphia, launched with a $100 million series A financing to focus on tackling central nervous system diseases. CEO Min Li told BioWorld the startup is “building a CNS portfolio through a combination of internal R&D and strategic collaborations.” Lilly Asia Ventures Fund and Arch Venture Partners co-led the round. Read More

Chimeric closes AU$35M IPO to progress CAR T made from scorpion toxin

PERTH, Australia – Chimeric Therapeutics Ltd. closed an IPO on the Australian Securities Exchange (ASX:CHM), raising AU$35 million (US$26.5 million) to fund its CAR T trial in glioblastoma. Read More

Skeletal disorder firm Innoskel launches with $24M

LONDON – Innoskel has arrived on the scene with a €20 million (US$24.3 million) series A funding to advance development of gene therapies for type 2 collagenopathies, a group of rare skeletal disorders that affect the structure of connective tissues, leading to short stature. Read More

Takeda wins China NMPA approval for Takhzyro for HAE prophylaxis

HONG KONG – Takeda Pharmaceutical Co. Ltd. has received Chinese approval for Takhzyro (lanadelumab), its fully human monoclonal antibody, delivered via subcutaneous injection, for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 and older. Read More
Test-tubes_dropper2.png

China’s I-Mab progresses anti-CD47 monoclonal antibody, caps strong financial year

Three months after completing what it said was the largest development and commercialization deal by a Chinese biotech, I-Mab Biopharma Co. Ltd. is moving the monoclonal antibody at the heart of the deal deeper into the clinic. At the end of November, Chinese regulators gave it a green light to move forward with an open-label, multicenter trial for lemzoparlimab, in combination with azacitidine. Read More

MHRA: Trial supply chains need to prepare for Brexit changes

The latest global regulatory news, changes and updates affecting biopharma, including: Health Canada to extend COVID-19 flexibilities; USTR seeking input on nations with poor IP protections. Read More
ICYMI illustration

ICYMI: Week in review, Dec. 7-11, 2020

A quick look back at top stories. Read More

Financings for Dec. 14, 2020

Biopharmas raising money in public or private financings, including: 9 Meters, Curis, Hookipa, IGM, Kura, Locanabio, Mirum. Read More

Other news to note for Dec. 14, 2020

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 3Sbio, ADC, Adelia, Allarity, Alzecure, Anixa, Ascentage, Ashvattha, Brainstorm Cell, Crispr, Cybin, Enzolytics, Eureka, Havn, Hemab, Hummingbird, Immuno-Precise, Intellia, Litevax, Mosaic, Neuraxpharm, Neurorx, Novo Nordisk, Overland, Pharmacyte, Phathom, Reviva, Spectrum, Teon, Unicycive, Verseau, Vivus. Read More

In the clinic for Dec. 14, 2020

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aerpio, Amarin, Arvinas, Astrazeneca, Bellus, Biontech, Biophytis, Caladrius, Cytokinetics, Curevac, Daiichi, Freeline, Innovent, Junshi, Kintor, Lilly, Mitsubishi Tanabe, Novartis, Odonate, Pfizer, Polyphor, Poxel, Puma, RDIF, Sanofi, Synlogic, TCR2. Read More

Regulatory actions for Dec. 14, 2020

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Acceleron, Amag, Ascletis, Antengene, Astrazeneca, Avelas, Biontech, Codagenix, Daiichi Sankyo, EMD, Gamida, Gannex, Graphite, Legend, Merck KGaA, Mindmed, Open Orphan, Pfizer, Sobi. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 13, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 13, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe